Related Experiment Video
Updated: Jun 6, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Implantable cardioverter defibrillator: charge saver, not syncope saver!
Diego Chemello1, Anandaraja Subramanian, Sheila Watkins
1The Hull Family Cardiac Fibrillation Management Laboratory, Toronto General Hospital, Toronto, Ontario.
Abstract:
In patients with an implantable cardioverter defibrillator, empirical antitachycardia pacing/burst pacing (ATP) is associated with a significantly decreased rate of appropriate shocks. The use of ATP as first-line therapy in ventricular tachycardia promotes less pain and better quality of life because the number of shocks is reduced. Additionally, battery longevity is substantially increased with this strategy. Based on this, device manufacturers have developed new algorithms to optimize the use of ATP and shocks in patients with an implantable cardioverter defibrillator. The present report describes a case in which the use of one of these new algorithms was associated with a significant delay in tachycardia termination and, consequently, led to syncope.
Related Concept Videos
Cardiopulmonary Resuscitation III: AED Use
Cardiomyopathy V: Interprofessional Care
Dysrhythmias VI: Management of Dysrhythmias
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
